Main Library

Why Value-Based Business Models Are Core to 2022 Investment Activity

November 9, 2022Ben GrabskiLumerisBest Practices & Strategies for Success,Transitioning to VBC,VBC Development, Growth & Expansion,CMS, CMMI, Government, Policy & Regulations

The introduction of the phrase “value-based care” into the industry lexicon can be tracked back to 2010 driven by the reforms of the Affordable Care Act (ACA). The HMOs of the 1990s weren’t balanced with quality, access, consumerism, nor were they tech enabled. They indeed failed spectacularly but moving back to FFS indefinitely wasn’t the answer either.  Lessons learned were applied to the Medicare Advantage modernization aspects of the ACA to align quality, cost and consumerism. The ACA also came with the commitment from the government for continued payment model innovation through the Center for Medicare and Medicaid Innovation (CMMI) which started a new value-based care arms race in the private sector.

There was a lot of experimentation and innovation from 2010-2020 and we are now starting to see the promise of value-based care prove itself out with sustainable, value-creating healthcare companies. In fact, CMS has doubled down on the trajectory and commitment of value-based care over FFS with the creation of its most advanced payment model yet, ACO REACH, and with the goal of all Medicare and Medicaid beneficiaries to be in a value-based model by 2030.  Value-based care is no longer an experiment, and the equity markets have noticed.

To be clear, I am not talking about the exuberance we saw in the Special Purpose Acquisition Company (SPAC) markets in 2020 and 2021. Most of the SPAC companies were NewCos built on the promise of value, often through a PowerPoint presentation, with little to no operating history, capitalizing on the market’s desire to get in on these companies early, in a desirable sector, when the market was flush with capital.  But it takes more than a PowerPoint to deliver on the promise of value-based care. Value-based care is simple in concept but incredibly difficult to execute. This was demonstrated by many of these SPAC companies missing their FIRST quarter commitments and trading down 90% of their initial stock price.  Experience matters in value-based care.

Where the equity markets have maintained, and increased valuations are with companies that are already (or are close to) cash flow positive and have a track record adding value to the healthcare supply chain. Deals that involve value-based payment, continuum of care coordination, and ease of access consumerism have been the focus recently.

Sherlock Company, a research organization that tracks the state of investment in public value-based care companies, states seven value-based care public companies it follows had revenue growth of nearly 100% year-over-year, and outperformed the greater S&P 500, even in the broader bear market.

Full Article

Visit the Lumeris Exhibit Booth

Recent Posts

  • RECORDED WEBINAR: Best Value-Based Care Strategies PT 2: Controlling Specialty Patient Care Costs and Total Costs for Negotiating Leverage
  • Jefferson Health’s strategy to optimize value-based care
  • Value-based payment, oncology and primary care — how can it all work together?
  • RECORDED WEBINAR: Conquering Readmissions: Proven Strategies and the Power of Digital Health in Value-Based Models
  • RECORDED WEBINAR: Best Value-Based Care Strategies PT 1: Strategically Managing Your VBC Program w/ MA/ACO & Changes in Payment Models
 
  • Main Lobby
  • Exhibit Hall
  • Events
  • Exhibit With Us
  • Board Room
  • Library
  • Contact Us